NCT03947190View on ClinicalTrials.gov

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

February 26, 2023

Study Completion Date

February 26, 2023

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

R21/Matrix-M

R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

BIOLOGICAL

ChAd63/MVA ME-TRAP

ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.

BIOLOGICAL

intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge

PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.

Trial Locations (1)

PO Box 230, 80108

KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast, Kilifi

Sponsors
All Listed Sponsors
collaborator

Kenya Medical Research Institute

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

University of Oxford

OTHER